Cargando…

The effects of safinamide on dysphagia in Parkinson’s disease

Dysphagia is a potentially fatal symptom of Parkinson’s disease (PD) and is characterized by frequent silent aspiration, a risk factor for aspiration pneumonia. The transdermal dopamine agonist rotigotine alleviates dysphagia in patients with PD and is more effective than oral levodopa, suggesting t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirano, Makito, Samukawa, Makoto, Isono, Chiharu, Nagai, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212188/ https://www.ncbi.nlm.nih.gov/pubmed/37228084 http://dx.doi.org/10.1371/journal.pone.0286066

Ejemplares similares

Noncoding repeat expansions for ALS in Japan are associated with the ATXN8OS gene
por: Hirano, Makito, et al.
Publicado: (2018)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Memantine administration prevented chorea movement in Huntington’s disease: a case report
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2015)

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients
por: Cattaneo, Carlo, et al.
Publicado: (2020)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

Overall Efficacy and Safety of Safinamide in Parkinson’s Disease: A Systematic Review and a Meta-analysis
por: Giossi, Riccardo, et al.
Publicado: (2021)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study
por: De Micco, Rosa, et al.
Publicado: (2021)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
por: Bergmans, Bruno, et al.
Publicado: (2022)

Dysphagia for medication in Parkinson’s disease
por: Labeit, Bendix, et al.
Publicado: (2022)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE
por: Cattaneo, Carlo, et al.
Publicado: (2016)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ei3pcug2egmhmktrst7qd06t28